0001193125-22-273298 Sample Contracts

REGISTRATION RIGHTS AGREEMENT

Registration Rights Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Registration Rights Agreement
• Filed
  October 31st, 2022
• Company
  Taysha Gene Therapies, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of October 21, 2022, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas Texas, 75247 and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) a Delaware corporation (the “Purchaser”), with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108 and shall become effective as of the Closing.

SECURITIES PURCHASE AGREEMENT

Securities Purchase Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Securities Purchase Agreement
• Filed
  October 31st, 2022
• Company
  Taysha Gene Therapies, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2022, by and between Taysha Gene Therapies, Inc., a Delaware corporation (the “Company”), with its principal place of business at 3000 Pegasus Park Drive, Ste 1430, Dallas, Texas, 75247 and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) a Delaware corporation (the “Purchaser”) with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108. Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.

CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS AGREEMENT (INDICATED BY “[***]”) BECAUSE TAYSHA GENE THERAPIES, INC. HAS DETERMINED SUCH INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OPTION AGREEMENT

Option Agreement • October 31st, 2022 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Option Agreement
• Filed
  October 31st, 2022
• Company
  Taysha Gene Therapies, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

This Option Agreement (this “Agreement”) is dated as of October 21, 2022 (the “Effective Date”) by and between Taysha Gene Therapies, Inc., with a place of business at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (“Taysha”) and Audentes Therapeutics, Inc. (d/b/a Astellas Gene Therapy) with its principal place of business at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Astellas”). Taysha and Astellas may be referred to herein as a “Party” or, collectively, as “Parties”.